• Je něco špatně v tomto záznamu ?

Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies

R. Hájek, J. Jarkovsky, V. Maisnar, L. Pour, I. Špička, J. Minařík, E. Gregora, P. Kessler, M. Sýkora, H. Fraňková, M. Campioni, L. DeCosta, M. Treur, S. Gonzalez-McQuire, W. Bouwmeester,

. 2018 ; 18 (6) : e219-e240. [pub] 20180417

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, pozorovací studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035225

INTRODUCTION: Real-world data on patient outcomes and treatment patterns in multiple myeloma (MM) are limited. MATERIALS AND METHODS: The present noninterventional, observational, retrospective analysis of prospectively collected Czech patient medical record data from the Registry of Monoclonal Gammopathies estimated real-world outcomes in adults with a diagnosis of symptomatic MM made between May 2007 and June 2014. RESULTS: In total, 2446 patients had initiated first-line treatment. The median overall survival since the diagnosis (primary endpoint) was 50.3 months (95% confidence interval, 46.1-54.5 months) and decreased with each successive treatment line. A similar trend was observed for progression-free survival and the depth of response. In line with European guidelines and clinical practice, bortezomib-, thalidomide-, and lenalidomide-based regimens were most commonly used across all treatment lines (42.3%, 28.9%, and 18.4%, respectively). In the first line, bortezomib and thalidomide were used most often, with lenalidomide the most commonly used agent in the relapse setting (second to fourth lines). Exploratory analyses revealed that younger age (≤ 65 years), lower international staging system stage, and previous stem cell transplantation were associated with significant improvements in overall and progression-free survival, especially in the early treatment lines. CONCLUSION: The present study is the first analysis of Czech data from the Registry of Monoclonal Gammopathies, and it provides important insights into the real-world management of MM for physicians and healthcare providers.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035225
003      
CZ-PrNML
005      
20191014094125.0
007      
ta
008      
191007s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clml.2018.04.003 $2 doi
035    __
$a (PubMed)29793653
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hájek, Roman $u Department of Hemato-oncology, University Hospital Ostrava, Ostrava, Czech Republic; Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. Electronic address: roman.hajek@fno.cz.
245    10
$a Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies / $c R. Hájek, J. Jarkovsky, V. Maisnar, L. Pour, I. Špička, J. Minařík, E. Gregora, P. Kessler, M. Sýkora, H. Fraňková, M. Campioni, L. DeCosta, M. Treur, S. Gonzalez-McQuire, W. Bouwmeester,
520    9_
$a INTRODUCTION: Real-world data on patient outcomes and treatment patterns in multiple myeloma (MM) are limited. MATERIALS AND METHODS: The present noninterventional, observational, retrospective analysis of prospectively collected Czech patient medical record data from the Registry of Monoclonal Gammopathies estimated real-world outcomes in adults with a diagnosis of symptomatic MM made between May 2007 and June 2014. RESULTS: In total, 2446 patients had initiated first-line treatment. The median overall survival since the diagnosis (primary endpoint) was 50.3 months (95% confidence interval, 46.1-54.5 months) and decreased with each successive treatment line. A similar trend was observed for progression-free survival and the depth of response. In line with European guidelines and clinical practice, bortezomib-, thalidomide-, and lenalidomide-based regimens were most commonly used across all treatment lines (42.3%, 28.9%, and 18.4%, respectively). In the first line, bortezomib and thalidomide were used most often, with lenalidomide the most commonly used agent in the relapse setting (second to fourth lines). Exploratory analyses revealed that younger age (≤ 65 years), lower international staging system stage, and previous stem cell transplantation were associated with significant improvements in overall and progression-free survival, especially in the early treatment lines. CONCLUSION: The present study is the first analysis of Czech data from the Registry of Monoclonal Gammopathies, and it provides important insights into the real-world management of MM for physicians and healthcare providers.
650    _2
$a věkové faktory $7 D000367
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a bortezomib $x terapeutické užití $7 D000069286
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a lenalidomid $x terapeutické užití $7 D000077269
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x mortalita $x patologie $x terapie $7 D009101
650    _2
$a staging nádorů $7 D009367
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a prospektivní studie $7 D011446
650    _2
$a registrace $x statistika a číselné údaje $7 D012042
650    _2
$a retrospektivní studie $7 D012189
650    12
$a transplantace kmenových buněk $7 D033581
650    _2
$a analýza přežití $7 D016019
650    _2
$a thalidomid $x terapeutické užití $7 D013792
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Jarkovsky, Jiri $u Institute of Biostatistics and Analyses, Faculty of Medicine and Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Maisnar, Vladimír $u Fourth Department of Medicine - Hematology, Charles University Hospital and Faculty of Medicine, Charles University, Hradec Králové, Czech Republic.
700    1_
$a Pour, Ludek $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine Masaryk University, Brno, Czech Republic.
700    1_
$a Špička, Ivan $u First Medical Department - Clinical Department of Haematology, First Faculty of Medicine and General Teaching Hospital, Charles University, Prague, Czech Republic.
700    1_
$a Minařík, Jiri $u Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic.
700    1_
$a Gregora, Evžen $u Department of Internal Medicine and Hematology, University Hospital Královské Vinohrady, Prague, Czech Republic.
700    1_
$a Kessler, Petr $u Department of Hematology and Transfusion Medicine, Hospital Pelhřimov, Pelhřimov, Czech Republic.
700    1_
$a Sýkora, Michal $u Department of Clinical Hematology, Hospital České Budějovice, České Budějovice, Czech Republic.
700    1_
$a Fraňková, Hana $u Department of Hematology, General Hospital Liberec, Liberec, Czech Republic.
700    1_
$a Campioni, Marco $u Amgen (Europe) GmbH, Zug, Switzerland.
700    1_
$a DeCosta, Lucy $u Amgen Ltd., Uxbridge, UK.
700    1_
$a Treur, Maarten $u Pharmerit International, Rotterdam, Netherlands.
700    1_
$a Gonzalez-McQuire, Sebastian $u Amgen (Europe) GmbH, Zug, Switzerland.
700    1_
$a Bouwmeester, Walter $u Pharmerit International, Rotterdam, Netherlands.
773    0_
$w MED00180199 $t Clinical lymphoma, myeloma & leukemia $x 2152-2669 $g Roč. 18, č. 6 (2018), s. e219-e240
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29793653 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191014094549 $b ABA008
999    __
$a ok $b bmc $g 1451885 $s 1073775
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 18 $c 6 $d e219-e240 $e 20180417 $i 2152-2669 $m Clinical lymphoma, myeloma & leukemia $n Clin Lymphoma Myeloma Leuk $x MED00180199
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace